Omnio AB raises 5.5MSEK in fundraising round

SWEDEN, 6th December, 2021 - Omnio AB is developing new drug products based on the pro-inflammatory and immune regulatory effects of the serum protein plasminogen. During fall the company successfully raised 5.5MSEK in a new share issue and welcomed four new investors to the company. The added investments make it possible for the company to now initiate its planned activities to develop recombinant plasminogen for treatment of diabetic foot ulcers.

Omnio AB receives patent for use of inhibitors of plasminogen for treating, reducing or preventing radiation-induced injuries

Research group at Umeå University publishes paper on the regulation of wound healing by the plasminogen receptor, Plg-RKT

Omnio AB receives support from SweLife together with Umeå University and the county of Västerbotten to develop biological treatments for periodontitis and peri-implantitis

Omnio together with Umeå university and the county council selected by the Vinnova program SweLife receive support of a total of SEK 3 million to develop new treatments for periodontitis and peri-implantitis. In competition with 120 applications, 16 were selected that were considered to have the greatest potential to lead to future better health. Omnio's project was one of these.

Research group at Umeå University publishes paper on Plasminogens role in radiation induced dermatitis

Professor Tor Ny receives a 6 MSEK grant from the Erling-Persson foundation over three years for the project "Plasminogen: a novel pro-inflammatory drug to combat infections by antibiotic-resistant bacteria"

Professor Tor Ny publish article in Thrombosis and Haemostasis on Plasminogens role in cutaneous wound healing